|
WO2012019630A1
(en)
|
2010-08-13 |
2012-02-16 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
|
|
WO2012116714A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in elderly patients
|
|
WO2013120499A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
|
|
WO2013120497A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
|
|
CA2859452C
(en)
|
2012-03-27 |
2021-12-21 |
Curevac Gmbh |
Artificial nucleic acid molecules for improved protein or peptide expression
|
|
WO2014127917A1
(en)
|
2013-02-22 |
2014-08-28 |
Curevac Gmbh |
Combination of vaccination and inhibition of the pd-1 pathway
|
|
WO2015024669A1
(en)
|
2013-08-21 |
2015-02-26 |
Curevac Gmbh |
Combination vaccine
|
|
CN105517569A
(zh)
|
2013-08-21 |
2016-04-20 |
库瑞瓦格股份公司 |
狂犬病疫苗
|
|
AU2014310933B2
(en)
|
2013-08-21 |
2020-05-14 |
CureVac SE |
Method for increasing expression of RNA-encoded proteins
|
|
CA2915728A1
(en)
|
2013-08-21 |
2015-02-26 |
Thomas Kramps |
Respiratory syncytial virus (rsv) vaccine
|
|
ES2806575T3
(es)
|
2013-11-01 |
2021-02-18 |
Curevac Ag |
ARN modificado con propiedades inmunoestimuladoras disminuidas
|
|
WO2015101415A1
(en)
|
2013-12-30 |
2015-07-09 |
Curevac Gmbh |
Artificial nucleic acid molecules
|
|
CN111304231A
(zh)
|
2013-12-30 |
2020-06-19 |
库瑞瓦格股份公司 |
人工核酸分子
|
|
AU2014375404C1
(en)
|
2013-12-30 |
2020-11-19 |
CureVac Manufacturing GmbH |
Methods for RNA analysis
|
|
US11254951B2
(en)
|
2014-12-30 |
2022-02-22 |
Curevac Ag |
Artificial nucleic acid molecules
|
|
ES2754239T3
(es)
|
2014-03-12 |
2020-04-16 |
Curevac Ag |
Combinación de vacunación y agonistas de OX40
|
|
CA2936286A1
(en)
|
2014-04-01 |
2015-10-08 |
Curevac Ag |
Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
|
|
US10837039B2
(en)
|
2014-06-10 |
2020-11-17 |
Curevac Real Estate Gmbh |
Methods and means for enhancing RNA production
|
|
IL316479A
(en)
|
2014-06-25 |
2024-12-01 |
Acuitas Therapeutics Inc |
Novel lipids and lipid nanoparticle compositions for nucleic acid delivery
|
|
ES2946969T3
(es)
|
2014-12-12 |
2023-07-28 |
CureVac SE |
Moléculas de ácido nucleico artificiales para una expresión proteica mejorada
|
|
JP6907116B2
(ja)
*
|
2014-12-30 |
2021-07-21 |
キュアバック アーゲー |
人工核酸分子
|
|
EP3283059B1
(en)
|
2015-04-13 |
2024-01-03 |
CureVac Manufacturing GmbH |
Method for producing rna compositions
|
|
CN107567497A
(zh)
|
2015-04-17 |
2018-01-09 |
库瑞瓦格股份公司 |
Rna的冻干
|
|
EP3173092B1
(en)
|
2015-04-22 |
2019-06-26 |
CureVac AG |
Rna containing composition for treatment of tumor diseases
|
|
JP2018526321A
(ja)
|
2015-04-27 |
2018-09-13 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
適応免疫応答を誘導するためのヌクレオシド修飾rna
|
|
WO2016174271A1
(en)
|
2015-04-30 |
2016-11-03 |
Curevac Ag |
Immobilized poly(n)polymerase
|
|
DK3294885T3
(da)
|
2015-05-08 |
2020-08-10 |
Curevac Real Estate Gmbh |
Fremgangsmåde til at fremstille rna
|
|
JP6893177B2
(ja)
|
2015-05-15 |
2021-06-23 |
キュアバック アーゲー |
少なくとも1つのmRNAコンストラクトの投与を含むプライムブーストレジメン(PRIME−BOOST REGIMENS)
|
|
SG10201910431RA
(en)
|
2015-05-20 |
2020-01-30 |
Curevac Ag |
Dry powder composition comprising long-chain rna
|
|
WO2016184576A2
(en)
|
2015-05-20 |
2016-11-24 |
Curevac Ag |
Dry powder composition comprising long-chain rna
|
|
PL4108769T3
(pl)
|
2015-05-29 |
2024-02-05 |
CureVac Manufacturing GmbH |
Sposób wytwarzania i oczyszczania rna obejmujący co najmniej jeden etap filtracji o przepływie stycznym
|
|
EP4098743A1
(en)
|
2015-05-29 |
2022-12-07 |
CureVac AG |
Method for adding cap structures to rna using immobilized enzymes
|
|
HUE067372T2
(hu)
|
2015-06-29 |
2024-10-28 |
Acuitas Therapeutics Inc |
Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására
|
|
US10501768B2
(en)
|
2015-07-13 |
2019-12-10 |
Curevac Ag |
Method of producing RNA from circular DNA and corresponding template DNA
|
|
KR102645398B1
(ko)
|
2015-08-28 |
2024-03-07 |
큐어백 에스이 |
신규 인공 핵산 분자
|
|
RS63030B1
(sr)
|
2015-09-17 |
2022-04-29 |
Modernatx Inc |
Jedinjenja i kompozicije za intracelularno isporučivanje terapeutskih sredstava
|
|
WO2017059902A1
(en)
*
|
2015-10-07 |
2017-04-13 |
Biontech Rna Pharmaceuticals Gmbh |
3' utr sequences for stabilization of rna
|
|
US11225682B2
(en)
|
2015-10-12 |
2022-01-18 |
Curevac Ag |
Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
|
|
WO2017066782A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Hydrophobic mrna cap analogs
|
|
WO2017066781A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Mrna cap analogs with modified phosphate linkage
|
|
WO2017066791A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Sugar substituted mrna cap analogs
|
|
WO2017066789A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Mrna cap analogs with modified sugar
|
|
JP2018530587A
(ja)
|
2015-10-16 |
2018-10-18 |
モデルナティエックス インコーポレイテッドModernaTX,Inc. |
mRNAキャップ類似体およびmRNAキャッピングの方法
|
|
MD3718565T2
(ro)
|
2015-10-22 |
2022-09-30 |
Modernatx Inc |
Vaccinuri împotriva virusului respirator
|
|
RS63986B1
(sr)
|
2015-10-28 |
2023-03-31 |
Acuitas Therapeutics Inc |
Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina
|
|
WO2017081082A2
(en)
|
2015-11-09 |
2017-05-18 |
Curevac Ag |
Optimized nucleic acid molecules
|
|
WO2017081110A1
(en)
|
2015-11-09 |
2017-05-18 |
Curevac Ag |
Rotavirus vaccines
|
|
JP6949845B2
(ja)
|
2015-12-22 |
2021-10-13 |
キュアバック アーゲー |
Rna分子組成物の作製方法
|
|
JP7114465B2
(ja)
|
2015-12-22 |
2022-08-08 |
モデルナティエックス インコーポレイテッド |
薬剤の細胞内送達のための化合物および組成物
|
|
US11248223B2
(en)
|
2015-12-23 |
2022-02-15 |
Curevac Ag |
Method of RNA in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
|
|
EP3405579A1
(en)
|
2016-01-22 |
2018-11-28 |
Modernatx, Inc. |
Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
|
|
EP4289965A3
(en)
|
2016-02-12 |
2024-02-21 |
CureVac SE |
Method for analyzing rna
|
|
US11723967B2
(en)
|
2016-02-17 |
2023-08-15 |
CureVac SE |
Zika virus vaccine
|
|
US11920174B2
(en)
|
2016-03-03 |
2024-03-05 |
CureVac SE |
RNA analysis by total hydrolysis and quantification of released nucleosides
|
|
US20190167811A1
(en)
|
2016-04-13 |
2019-06-06 |
Modernatx, Inc. |
Lipid compositions and their uses for intratumoral polynucleotide delivery
|
|
EP3445392A1
(en)
*
|
2016-04-22 |
2019-02-27 |
CureVac AG |
Rna encoding a tumor antigen
|
|
WO2017186928A1
(en)
|
2016-04-29 |
2017-11-02 |
Curevac Ag |
Rna encoding an antibody
|
|
EP4233898A3
(en)
|
2016-05-04 |
2023-11-01 |
CureVac SE |
Influenza mrna vaccines
|
|
WO2017191264A1
(en)
|
2016-05-04 |
2017-11-09 |
Curevac Ag |
Nucleic acid molecules and uses thereof
|
|
WO2017191274A2
(en)
|
2016-05-04 |
2017-11-09 |
Curevac Ag |
Rna encoding a therapeutic protein
|
|
US12128113B2
(en)
|
2016-05-18 |
2024-10-29 |
Modernatx, Inc. |
Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
|
|
DK3458083T5
(da)
|
2016-05-18 |
2024-10-21 |
Modernatx Inc |
Polynukleotider, der koder for interleukin-12 (il12), og anvendelser heraf
|
|
CN109475640B
(zh)
|
2016-06-09 |
2023-03-10 |
库瑞瓦格欧洲公司 |
核酸被运载物的混合载运体
|
|
WO2017218704A1
(en)
|
2016-06-14 |
2017-12-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
AU2017345766A1
(en)
*
|
2016-10-21 |
2019-05-16 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
US11583504B2
(en)
|
2016-11-08 |
2023-02-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
KR20190090836A
(ko)
*
|
2016-11-28 |
2019-08-02 |
나파젠 파마, 인크. |
화학 수식 siRNA
|
|
WO2018096179A1
(en)
|
2016-11-28 |
2018-05-31 |
Curevac Ag |
Method for purifying rna
|
|
AU2017368050A1
(en)
|
2016-11-29 |
2019-06-20 |
Puretech Lyt, Inc. |
Exosomes for delivery of therapeutic agents
|
|
EP3551193A4
(en)
|
2016-12-08 |
2020-08-19 |
Modernatx, Inc. |
NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES
|
|
US11542490B2
(en)
|
2016-12-08 |
2023-01-03 |
CureVac SE |
RNAs for wound healing
|
|
EP3808380A1
(en)
*
|
2016-12-08 |
2021-04-21 |
CureVac AG |
Rna for treatment or prophylaxis of a liver disease
|
|
WO2018115507A2
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Henipavirus vaccine
|
|
WO2018115527A2
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Mers coronavirus vaccine
|
|
US11464847B2
(en)
|
2016-12-23 |
2022-10-11 |
Curevac Ag |
Lassa virus vaccine
|
|
BR112019014314A2
(pt)
|
2017-01-11 |
2020-02-18 |
The Trustees Of The University Of Pennsylvania |
Composição, e, método de indução de uma resposta imune adaptativa contra vírus zika.
|
|
ES3020935T3
(en)
|
2017-03-15 |
2025-05-23 |
Modernatx Inc |
Lipid nanoparticle formulation
|
|
KR20190132405A
(ko)
|
2017-03-15 |
2019-11-27 |
모더나티엑스, 인크. |
치료제의 세포내 전달을 위한 화합물 및 조성물
|
|
WO2018170347A1
(en)
|
2017-03-17 |
2018-09-20 |
Modernatx, Inc. |
Zoonotic disease rna vaccines
|
|
CN110914433A
(zh)
|
2017-03-24 |
2020-03-24 |
库尔维科公司 |
编码crispr相关蛋白质的核酸及其用途
|
|
WO2018191657A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
|
CA3061326A1
(en)
|
2017-04-27 |
2018-11-01 |
The Johns Hopkins University |
Nucleoside-modified mrna-lipid nanoparticle lineage vaccine for hepatitis c virus
|
|
ES2981244T3
(es)
|
2017-04-28 |
2024-10-07 |
Acuitas Therapeutics Inc |
Novedosas formulaciones de nanopartículas de lípidos de carbonilo y lípidos para la administración de ácidos nucleicos
|
|
US12297489B2
(en)
|
2017-05-17 |
2025-05-13 |
CureVac Manufacturing GmbH |
Method for determining at least one quality parameter of an RNA sample
|
|
US12077501B2
(en)
|
2017-06-14 |
2024-09-03 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of agents
|
|
US20200131498A1
(en)
|
2017-06-14 |
2020-04-30 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase
|
|
BR112019028280A2
(pt)
|
2017-07-04 |
2020-07-14 |
Curevac Ag |
moléculas de ácido nucleico
|
|
US11639329B2
(en)
|
2017-08-16 |
2023-05-02 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
US11542225B2
(en)
|
2017-08-17 |
2023-01-03 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2019036030A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
|
|
EP4501322A3
(en)
|
2017-08-17 |
2025-04-16 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
WO2019036638A1
(en)
|
2017-08-18 |
2019-02-21 |
Modernatx, Inc. |
METHODS FOR PREPARING MODIFIED RNA
|
|
EP3673069A1
(en)
|
2017-08-22 |
2020-07-01 |
CureVac AG |
Bunyavirales vaccine
|
|
WO2019046809A1
(en)
|
2017-08-31 |
2019-03-07 |
Modernatx, Inc. |
METHODS OF MANUFACTURING LIPID NANOPARTICLES
|
|
US11692002B2
(en)
|
2017-11-08 |
2023-07-04 |
CureVac SE |
RNA sequence adaptation
|
|
EP3723796A1
(en)
|
2017-12-13 |
2020-10-21 |
CureVac AG |
Flavivirus vaccine
|
|
CN111511928A
(zh)
|
2017-12-21 |
2020-08-07 |
库瑞瓦格股份公司 |
偶联到单一支持物或标签的线性双链dna和用于制备所述线性双链dna的方法
|
|
WO2019148101A1
(en)
|
2018-01-29 |
2019-08-01 |
Modernatx, Inc. |
Rsv rna vaccines
|
|
WO2019193183A2
(en)
*
|
2018-04-05 |
2019-10-10 |
Curevac Ag |
Novel yellow fever nucleic acid molecules for vaccination
|
|
DE202019006199U1
(de)
|
2018-04-17 |
2026-01-12 |
CureVac SE |
Neue RSV-RNA-Moleküle und Zusammensetzungen für die Impfung
|
|
WO2020002598A1
(en)
|
2018-06-28 |
2020-01-02 |
Curevac Ag |
Bioreactor for rna in vitro transcription
|
|
WO2020061367A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
WO2020061457A1
(en)
|
2018-09-20 |
2020-03-26 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
IL281615B2
(en)
|
2018-09-21 |
2026-01-01 |
Acuitas Therapeutics Inc |
Systems and methods for producing lipid nanoparticles and liposomes
|
|
US12583816B2
(en)
|
2018-10-18 |
2026-03-24 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
|
US12270057B2
(en)
|
2018-11-05 |
2025-04-08 |
The University Of North Carolina At Chapel Hill |
Optimized FIG4 genes and expression cassettes and their use
|
|
TW202039534A
(zh)
|
2018-12-14 |
2020-11-01 |
美商美國禮來大藥廠 |
KRAS變體mRNA分子
|
|
US12492425B2
(en)
|
2018-12-21 |
2025-12-09 |
CureVac SE |
Methods for RNA analysis
|
|
KR20210133218A
(ko)
|
2019-01-31 |
2021-11-05 |
모더나티엑스, 인크. |
볼텍스 믹서 및 연계된 방법, 시스템 및 이의 장치
|
|
MX2021009245A
(es)
|
2019-01-31 |
2021-11-12 |
Modernatx Inc |
Metodos de preparacion de nanoparticulas lipidicas.
|
|
US11351242B1
(en)
|
2019-02-12 |
2022-06-07 |
Modernatx, Inc. |
HMPV/hPIV3 mRNA vaccine composition
|
|
US20230000908A1
(en)
*
|
2019-09-11 |
2023-01-05 |
Ohio State Innovation Foundation |
Engineered cells and uses thereof
|
|
CN114901360A
(zh)
|
2019-12-20 |
2022-08-12 |
库瑞瓦格股份公司 |
用于递送核酸的新型脂质纳米颗粒
|
|
JP2023511633A
(ja)
|
2020-01-28 |
2023-03-20 |
モデルナティエックス インコーポレイテッド |
コロナウイルスrnaワクチン
|
|
US12194089B2
(en)
|
2020-02-04 |
2025-01-14 |
CureVac SE |
Coronavirus vaccine
|
|
US11241493B2
(en)
|
2020-02-04 |
2022-02-08 |
Curevac Ag |
Coronavirus vaccine
|
|
AU2021215938A1
(en)
|
2020-02-07 |
2022-09-01 |
Modernatx, Inc. |
Sars-cov-2 mrna domain vaccines
|
|
KR102924173B1
(ko)
|
2020-04-09 |
2026-02-06 |
쑤저우 아보젠 바이오사이언시스 컴퍼니 리미티드 |
지질 나노입자 조성물
|
|
WO2021204179A1
(en)
|
2020-04-09 |
2021-10-14 |
Suzhou Abogen Biosciences Co., Ltd. |
Nucleic acid vaccines for coronavirus
|
|
WO2021222304A1
(en)
|
2020-04-27 |
2021-11-04 |
Modernatx, Inc. |
Sars-cov-2 rna vaccines
|
|
WO2021159130A2
(en)
|
2020-05-15 |
2021-08-12 |
Modernatx, Inc. |
Coronavirus rna vaccines and methods of use
|
|
AU2021301922A1
(en)
|
2020-06-30 |
2023-02-02 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
|
JP7798855B2
(ja)
|
2020-07-16 |
2026-01-14 |
アクイタス セラピューティクス インコーポレイテッド |
脂質ナノ粒子に使用するためのカチオン性脂質
|
|
WO2022037652A1
(en)
|
2020-08-20 |
2022-02-24 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
|
WO2022047325A1
(en)
*
|
2020-08-31 |
2022-03-03 |
The Trustees Of Columbia University In The City Of New York |
Targeting of tgm4 to treat prostate cancer
|
|
WO2022067010A1
(en)
|
2020-09-25 |
2022-03-31 |
Modernatx, Inc. |
Multi-proline-substituted coronavirus spike protein vaccines
|
|
US11771652B2
(en)
|
2020-11-06 |
2023-10-03 |
Sanofi |
Lipid nanoparticles for delivering mRNA vaccines
|
|
US20240156946A1
(en)
|
2020-12-22 |
2024-05-16 |
CureVac SE |
Rna vaccine against sars-cov-2 variants
|
|
WO2022150717A1
(en)
|
2021-01-11 |
2022-07-14 |
Modernatx, Inc. |
Seasonal rna influenza virus vaccines
|
|
WO2022152109A2
(en)
|
2021-01-14 |
2022-07-21 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
|
WO2022152141A2
(en)
|
2021-01-14 |
2022-07-21 |
Suzhou Abogen Biosciences Co., Ltd. |
Polymer conjugated lipid compounds and lipid nanoparticle compositions
|
|
US20240139309A1
(en)
|
2021-01-15 |
2024-05-02 |
Modernatx, Inc. |
Variant strain-based coronavirus vaccines
|
|
JP2024503698A
(ja)
|
2021-01-15 |
2024-01-26 |
モデルナティエックス インコーポレイテッド |
変異型株ベースのコロナウイルスワクチン
|
|
CN114908089B
(zh)
*
|
2021-02-08 |
2024-03-15 |
上海细胞治疗集团有限公司 |
3’utr的构建方法和应用
|
|
US20240299531A1
(en)
|
2021-03-15 |
2024-09-12 |
Moderna TX, Inc |
Therapeutic use of sars-cov-2 mrna domain vaccines
|
|
AU2022258335A1
(en)
|
2021-04-13 |
2023-11-23 |
Modernatx, Inc. |
Respiratory virus combination vaccines
|
|
WO2022221440A1
(en)
|
2021-04-14 |
2022-10-20 |
Modernatx, Inc. |
Influenza-coronavirus combination vaccines
|
|
WO2022245888A1
(en)
|
2021-05-19 |
2022-11-24 |
Modernatx, Inc. |
Seasonal flu rna vaccines and methods of use
|
|
WO2022247755A1
(en)
|
2021-05-24 |
2022-12-01 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
|
WO2022264109A1
(en)
|
2021-06-18 |
2022-12-22 |
Sanofi |
Multivalent influenza vaccines
|
|
EP4392140A1
(en)
|
2021-08-24 |
2024-07-03 |
BioNTech SE |
In vitro transcription technologies
|
|
EP4402121A1
(en)
|
2021-09-14 |
2024-07-24 |
Renagade Therapeutics Management Inc. |
Acyclic lipids and methods of use thereof
|
|
TW202328067A
(zh)
|
2021-09-14 |
2023-07-16 |
美商雷納嘉德醫療管理公司 |
環狀脂質及其使用方法
|
|
AR127312A1
(es)
|
2021-10-08 |
2024-01-10 |
Suzhou Abogen Biosciences Co Ltd |
Compuestos lipídicos ycomposiciones de nanopartículas lipídicas
|
|
CN116064598B
(zh)
|
2021-10-08 |
2024-03-12 |
苏州艾博生物科技有限公司 |
冠状病毒的核酸疫苗
|
|
AU2022358824A1
(en)
|
2021-10-08 |
2024-04-11 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compounds and lipid nanoparticle compositions
|
|
EP4419081A1
(en)
|
2021-10-22 |
2024-08-28 |
Sail Biomedicines, Inc. |
Mrna vaccine composition
|
|
TW202346593A
(zh)
|
2021-11-05 |
2023-12-01 |
法商賽諾菲公司 |
呼吸道融合病毒rna疫苗
|
|
WO2023092069A1
(en)
|
2021-11-18 |
2023-05-25 |
Modernatx, Inc. |
Sars-cov-2 mrna domain vaccines and methods of use
|
|
KR20240107356A
(ko)
|
2021-11-23 |
2024-07-09 |
세일 바이오메디슨스, 인크. |
박테리아-유래 지질 조성물 및 이의 용도
|
|
CA3239417A1
(en)
|
2021-11-30 |
2023-06-08 |
Yvonne CHAN |
Human metapneumovirus vaccines
|
|
EP4444345A2
(en)
|
2021-12-08 |
2024-10-16 |
ModernaTX, Inc. |
Herpes simplex virus mrna vaccines
|
|
CA3242402A1
(en)
|
2021-12-16 |
2023-06-22 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
|
CN119095613A
(zh)
|
2021-12-17 |
2024-12-06 |
赛诺菲 |
莱姆病rna疫苗
|
|
WO2023122080A1
(en)
|
2021-12-20 |
2023-06-29 |
Senda Biosciences, Inc. |
Compositions comprising mrna and lipid reconstructed plant messenger packs
|
|
CA3243054A1
(en)
|
2021-12-23 |
2025-04-08 |
Renagade Therapeutics Management Inc. |
Constrained Lipids and Associated Utilization Processes
|
|
CA3241492A1
(en)
|
2021-12-23 |
2023-06-29 |
Suzhou Abogen Biosciences Co., Ltd. |
Lipid compound and lipid nanoparticle composition
|
|
WO2023196931A1
(en)
|
2022-04-07 |
2023-10-12 |
Renagade Therapeutics Management Inc. |
Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents
|
|
WO2023196914A1
(en)
|
2022-04-08 |
2023-10-12 |
Modernatx, Inc. |
Influenza nucleic acid compositions and uses thereof
|
|
WO2023230481A1
(en)
|
2022-05-24 |
2023-11-30 |
Modernatx, Inc. |
Orthopoxvirus vaccines
|
|
WO2024015890A1
(en)
|
2022-07-13 |
2024-01-18 |
Modernatx, Inc. |
Norovirus mrna vaccines
|
|
JP2025527583A
(ja)
|
2022-08-18 |
2025-08-22 |
スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド |
脂質ナノ粒子の組成物
|
|
EP4577236A1
(en)
|
2022-08-22 |
2025-07-02 |
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. |
Vaccines against coronaviruses
|
|
WO2024050483A1
(en)
|
2022-08-31 |
2024-03-07 |
Modernatx, Inc. |
Variant strain-based coronavirus vaccines and uses thereof
|
|
WO2024083345A1
(en)
|
2022-10-21 |
2024-04-25 |
BioNTech SE |
Methods and uses associated with liquid compositions
|
|
EP4608442A1
(en)
|
2022-10-28 |
2025-09-03 |
GlaxoSmithKline Biologicals S.A. |
Nucleic acid based vaccine
|
|
JP2025536595A
(ja)
|
2022-11-04 |
2025-11-07 |
サノフィ パスツール インコーポレイテッド |
メッセンジャーrnaテール付加の方法
|
|
AU2023374764A1
(en)
|
2022-11-04 |
2025-06-19 |
Sanofi Pasteur Inc. |
Respiratory syncytial virus rna vaccination
|
|
WO2024102434A1
(en)
|
2022-11-10 |
2024-05-16 |
Senda Biosciences, Inc. |
Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs
|
|
EP4634207A1
(en)
|
2022-12-15 |
2025-10-22 |
Sanofi Pasteur Inc. |
Mrna recombinant capping enzymes
|
|
WO2024126809A1
(en)
|
2022-12-15 |
2024-06-20 |
Sanofi |
Mrna encoding influenza virus-like particle
|
|
WO2024133884A2
(en)
|
2022-12-23 |
2024-06-27 |
Sanofi |
Optimized tailing of messenger rna
|
|
KR20250153793A
(ko)
|
2023-01-27 |
2025-10-27 |
세일 바이오메디슨스, 인크. |
변형된 지질 조성물 및 이의 용도
|
|
EP4658306A1
(en)
|
2023-01-30 |
2025-12-10 |
ModernaTX, Inc. |
Epstein-barr virus mrna vaccines
|
|
JP2026504797A
(ja)
|
2023-03-02 |
2026-02-10 |
サノフィ・パスツール |
クラミジア(Chlamydia)の治療に使用するための組成物
|
|
CN120858173A
(zh)
|
2023-03-07 |
2025-10-28 |
赛诺菲巴斯德有限公司 |
用kp34聚合酶制造信使rna
|
|
CN121263402A
(zh)
|
2023-03-15 |
2026-01-02 |
雷纳嘉德医疗管理公司 |
用于基因编辑以及作为疫苗和治疗剂的包含编码rna分子的脂质纳米颗粒
|
|
AU2024236558A1
(en)
|
2023-03-15 |
2025-10-09 |
Renagade Therapeutics Management Inc. |
Delivery of gene editing systems and methods of use thereof
|
|
WO2024215721A1
(en)
|
2023-04-10 |
2024-10-17 |
Modernatx, Inc. |
Lyme disease vaccines
|
|
WO2024220712A2
(en)
|
2023-04-19 |
2024-10-24 |
Sail Biomedicines, Inc. |
Vaccine compositions
|
|
WO2024231727A1
(en)
|
2023-05-05 |
2024-11-14 |
Sanofi |
Compositions for use in treatment of acne
|
|
TW202508620A
(zh)
|
2023-05-10 |
2025-03-01 |
尼可拉斯 克拉克 |
呼吸道mrna組合疫苗
|
|
WO2024254552A1
(en)
|
2023-06-08 |
2024-12-12 |
Modernatx, Inc. |
Stabilized flavivirus vaccines
|
|
WO2024263826A1
(en)
|
2023-06-22 |
2024-12-26 |
Modernatx, Inc. |
Sars-cov-2 t cell vaccines
|
|
EP4734960A1
(en)
|
2023-06-28 |
2026-05-06 |
Sanofi Pasteur Inc. |
Sterol analogs in lipid nanoparticle formulations
|
|
WO2025019352A2
(en)
|
2023-07-14 |
2025-01-23 |
Modernatx, Inc. |
Mers-cov mrna vaccines
|
|
WO2025017151A1
(en)
|
2023-07-18 |
2025-01-23 |
Sanofi |
Stable poly(a)-encoding messenger rna templates
|
|
CN121889496A
(zh)
|
2023-07-19 |
2026-04-17 |
赛诺菲 |
牙龈卟啉单胞菌抗原构建体
|
|
WO2025029700A1
(en)
|
2023-07-28 |
2025-02-06 |
Modernatx, Inc. |
Vlp enteroviral vaccines
|
|
WO2025034612A1
(en)
|
2023-08-04 |
2025-02-13 |
Modernatx, Inc. |
Varicella-zoster virus mrna vaccine
|
|
WO2025049959A2
(en)
|
2023-09-01 |
2025-03-06 |
Renagade Therapeutics Management Inc. |
Gene editing systems, compositions, and methods for treatment of vexas syndrome
|
|
WO2025051975A1
(en)
|
2023-09-06 |
2025-03-13 |
Sanofi |
Modified influenza b hemagglutinin polypeptides and nucleic acids and uses thereof
|
|
AU2024357861A1
(en)
|
2023-10-12 |
2026-04-23 |
Renagade Therapeutics Management Inc. |
Nickase-retron template-based precision editing system and methods of use
|
|
WO2025128871A2
(en)
|
2023-12-13 |
2025-06-19 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2025134071A1
(en)
|
2023-12-22 |
2025-06-26 |
Sanofi |
Malic and glutaric acid based ionizable lipids
|
|
WO2025141521A1
(en)
|
2023-12-29 |
2025-07-03 |
Sanofi |
Lipids having dendritic moieties
|
|
WO2025155753A2
(en)
|
2024-01-17 |
2025-07-24 |
Renagade Therapeutics Management Inc. |
Improved gene editing system, guides, and methods
|
|
WO2025160191A2
(en)
*
|
2024-01-22 |
2025-07-31 |
The Board Of Trustees Of The Leland Stanford Junior University |
Composition and method for autonomous rna switches for translational control
|
|
WO2025174765A1
(en)
|
2024-02-12 |
2025-08-21 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2025210592A1
(en)
|
2024-04-05 |
2025-10-09 |
Sanofi Pasteur Inc. |
Muscle cell lnp-mrna quality control assays
|
|
WO2025226656A1
(en)
|
2024-04-23 |
2025-10-30 |
Modernatx, Inc. |
Hepatitis b virus mrna vaccines
|
|
WO2026008743A1
(en)
|
2024-07-02 |
2026-01-08 |
Sanofi Pasteur Inc. |
Water-soluble polyanionic polymer as adjuvant for carrier-formulated nucleic acid
|
|
WO2026027730A1
(en)
|
2024-07-31 |
2026-02-05 |
Sanofi |
Modified h5 influenza hemagglutinin polypeptides and nucleic acids and uses thereof
|
|
WO2026053147A1
(en)
|
2024-09-05 |
2026-03-12 |
Sanofi Pasteur Inc. |
Helper lipids and lnp compositions comprising same
|
|
WO2026052773A1
(en)
|
2024-09-06 |
2026-03-12 |
Sanofi |
Modified influenza a hemagglutinin polypeptides and nucleic acids and uses thereof
|
|
WO2026080379A1
(en)
|
2024-10-07 |
2026-04-16 |
Modernatx, Inc. |
Lyme disease mrna vaccines
|
|
WO2026093322A1
(en)
|
2024-10-28 |
2026-05-07 |
Sanofi Pasteur Inc. |
Improved dna constructs for manufacturing messenger rna by in vitro transcription
|